We are excited to invite you to view our webinar, "Launch Begins Drug Development," a look at possible continuing efforts to protect the drug product after launch. The panel dove into critical strategies and best practices to safeguard your product post-launch. This informative session was designed for professionals who are keen on understanding the nuances of product protection in the pharmaceutical industry, whether a startup with only one launched product or a well-established company with many products on the market.
Topics discussed:
ANDA Standards Advocacy
Understand how to effectively advocate for ANDA approval standards more rigorous than those suggested by the FDA’s product-specific guidance.
Learn about pitfalls to be avoided in advocating for such standards.
Prosecution Strategies for Continued Protection
Discover advanced prosecution strategies to maintain robust protection for your product.
Getting Ready for Litigation
Learn about pre-litigation strategies and how to build a strong defense.
Understand timing and the importance of litigation-readiness in protecting your product's market position.
Please note that CLE credit is only valid for live attendance. At this time, we are not able to provide credit for recorded views. Please contact us for details.
We use cookies to enhance user experience, improve functionality and performance, and for analysis of website traffic. By clicking “accept”, you agree to the use of cookies. For more information about our cookie policy and the information we collect, please review our Privacy Statement.
Foley Hoag
Email Disclaimer
Transmitting information to us by e-mail unilaterally does not establish an attorney-client relationship or impose an obligation on either the law firm or even the receiving lawyer to keep the transmitted information confidential. By clicking "OK," you acknowledge that we have no obligation to maintain the confidentiality of any information you submit to us unless we already represent you or unless we have agreed to receive limited confidential material/information from you as a prospective client. Thus, if you are not a client or someone we have agreed to consider as a prospective client, information you submit to us by e-mail may be disclosed to others or used against you.
If you would like to discuss becoming a client, please contact one of our attorneys to arrange for a meeting or telephone conference. If you wish to disclose confidential information to a lawyer in the firm before an attorney-client relationship is established, the protections that the law firm will provide to such information from a prospective client should be discussed before such information is submitted. Thank you for your interest in Foley Hoag.
